C3.2 R2: Participate in the development, revision, or implementation of a clinical protocol or pathway, checklist, or PPO

Based on new evidence and re-evaluation of prior evidence, the IDSA recently released revised guidelines for the treatment of C. difficile infection. The major change was that they now recommend vancomycin as first-line therapy for C. difficile of all severities (previously metronidazole was recommended as first-line treatment for the first episode of mild-moderate disease). Based … Continue reading C3.2 R2: Participate in the development, revision, or implementation of a clinical protocol or pathway, checklist, or PPO

Advertisements